Login to Your Account



Allergan Acquires Dermatology Assets with $275M Vicept Buy

By Catherine Shaffer


Wednesday, July 20, 2011
Allergan Inc. will acquire dermatology company Vicept Therapeutics Inc. in a deal worth up to $275 million. Malvern, Pa..-based Vicept's lead product, V-101, is in development for rosacea and has showed positive results in Phase II trials. The acquisition will beef up Allergan's range of dermatology products, which includes Tazorac (tazarotene) and Botox (onabotulinumtoxinA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription